Author Archives: Bruno Quinney

#Antibody-based therapeutics #Canada #Non-animal model (NAM)

Canadian companies to partner on novel antibody therapies 

VoxCell BioInnovation and adMare BioInnovations have announced a research partnership to advance novel antibody therapies in non-animal models.  VoxCell says its human-relevant vascularised tissue platform brings together human tumour, immune, and stromal compartments alongside a perfused, endothelial-lined vasculature in a single bioprinted construct.   The result is a… Read More

#News

Child with eczema
#Bacteria #Eczema #The University of Manchester

Bacteria could treat inflammatory skin conditions, research finds  

Skin bacteria could hold the key to safe treatments for eczema, new research suggests.  A study led by scientists at The University of Manchester and Tokyo University of Agriculture and Technology found that harmless microbes living on our skin release powerful molecules, shutting down inflammation triggered by Staphylococcus… Read More

#News

#Biotech #Infinitopes

Infinitopes appoints CSO to advance immuno-oncology pipeline 

Biotechnology company Infinitopes has appointed Jo Brewer as Chief Scientific Officer (CSO) and interim Chief Operating Officer (COO).  The company hopes Brewer’s appointment will allow it to advance a therapeutic pipeline of cancer therapies from clinical to commercialisation.  With 20 years of experience in advancing therapies from… Read More

#News

KRAS
#Cancer research #Clinical trial #KRAS #Protein

Targeting the undruggable protein: What is the potential for KRAS inhibitors? 

Diana Turner explores the latest KRAS breakthroughs and how our understanding of this illusive protein has developed in recent years.  In September 2025, the inaugural Stephenson Global Prize was awarded to Dr Frank McCormick, Professor at the UCSF Helen Diller Family Comprehensive Cancer Center, for “groundbreaking discoveries that have transformed the fight… Read More

#Cancer Research #Exclusive Content

Hepatitis B
#Gene editing #hepatitis #Precision BioSciences

Gene editing technology could treat Hepatitis B 

A gene editing technology has shown promising early results in treating patients with Hepatitis B.  Participants in the ELIMINATE-B trial were dosed in PBGENE-HBV, developed by gene editing company Precision BioSciences, at multiple ascending dose levels.   Results show PBGENE-HBV, which comprises an ARCUS-encoding mRNA encapsulated in a lipid nanoparticle… Read More

#News

MHRA
#Life sciences #MHRA #Northern Ireland

MHRA to open Northern Ireland hub to boost life sciences 

The Medicines and Healthcare products Regulatory Agency (MHRA) is opening a new hub in Northern Ireland to boost life sciences growth in the country.  The hub, hosted by Invest Northern Ireland, aims to build on MHRA’s partnerships in healthcare, academia and industry in Northern Ireland to ensure the work is… Read More

#News #Regulatory

#Parkinson's #R&D #UK

UK centre opens to accelerate Parkinson’s treatment research 

A new UK research centre has opened to accelerate the search for treatments for Parkinson’s disease.   The £10 million ($13.5 million) UK Dementia Research Institute Parkinson’s Research Centre, jointly funded with Parkinson’s UK, will connect research teams at the University of Edinburgh, the University of Oxford and University College London. Read More

#News

Cell and gene therapy concept
#Cell and gene therapy #Eli Lilly #FDA #Novo Nordisk #Takeda #Tregs

A bright future for advanced therapies 

2025 was a difficult year for cell and gene therapies (CGTs), as multiple companies discontinued their cell therapy efforts, including Galapagos, Novo Nordisk and Takeda, despite significant financial losses as a result. The complexity and expense of manufacturing the treatments has meant that even when they are approved, the therapies do not always reach the relevant patients. This, alongside… Read More

#Exclusive Content

#Affibody #Cancer research #Radiotherapy

A novel approach to HER2-targeted radiotherapy 

Fredrik Frejd, Chief Scientific Officer at Affibody, explains how the company’s radiotherapeutic candidate could address some of the limitations inherent in current approaches.  The field of targeted radiopharmaceuticals has witnessed remarkable growth in recent years, driven by blockbuster successes of Novartis' Lutathera (lutetium Lu 177 dotatate) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which together generated over $2 billion in sales in… Read More

#Exclusive Content

Mother helps child to use a nebuliser
#Clinical trial #Cystic fibrosis #Enterprise Therapeutics

Cystic fibrosis treatment could improve lung function 

A new treatment for cystic fibrosis (CF) could improve lung function in patients, results suggest.  ETD001, developed by biopharmaceutical company Enterprise Therapeutics, was trialled in a Phase II study as an inhaled treatment in the 10% of people with CF with the highest unmet medical need, who do… Read More

#News

Scientist in laboratory
#AI #Clinical trial #Phesi

AI not solving clinical trial flaws, report says 

AI tools are scaling flaws in clinical trials instead of solving them, analysis shows.  Analytics and data company Phesi revealed the findings from a global analysis of more than 600,000 clinical trial protocols.   Results show fewer than one in three (29.3%) protocols are linked to publicly documented patient… Read More

#News

Cancer research
#Antibody drug conjugate (ADC) #Cancer research #CAR T-cell therapy #KRAS #Radiopharmaceuticals

New tactics against hard-to-treat cancers

It is an exciting time in cancer drug discovery. Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s, according to the American Cancer Society’s 2026 Cancer Statistics.  New modalities, like radiopharmaceuticals, alongside new drug targets, like KRAS mutations, are resulting in therapies that… Read More

#Cancer Research #Exclusive Content

#Autoimmune disease #Clinical trial #FDA

FDA treatment approval brings ‘hope’ to gMG patients 

The US Food and Drug Administration (FDA) has approved the first treatments for all serotypes of patients living with generalised myasthenia gravis (gMG).  The FDA’s label expansion of Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) now means gMG adult patients can treat all serotypes, including anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and triple seronegative. … Read More

#News #Regulatory

#Biotech #Cell and gene therapy #Cell and Gene Therapy Catapult #UK

How strong is the UK’s advanced therapy sector?  

DDW Editor Reece Armstrong speaks to Jacqueline Barry, Chief Clinical Officer at Cell and Gene Therapy Catapult, about the UK’s strong position in advanced therapies and what the challenges are for making the country competitive within pharma.   RA: Why does the UK have a strong in position in clinical research for advanced therapies? … Read More

#Exclusive Content

#ASGCT #Cell and gene therapy #Clinical trial #Haematology

Therapy for X-CGD shows early promise, Ensoma reports 

An in vivo therapy being developed to treat X-linked chronic granulomatous disease (X-CGD) has shown positive early results.  EN-374, developed by cellular engineering company Ensoma, has demonstrated tolerability in the first participant being evaluated in the Phase I/II trial.  The therapy is a first-in-class in vivo haematopoietic stem cell… Read More

#News